title: Initiation and development of experimental autoimmune neuritis in Lewis rats is independent of the cytotoxic capacity of NKR-P1A+ cells.
abstract: Natural killer (NK) cells are implicated in T cell-mediated autoimmune diseases. Experimental autoimmune neuritis (EAN) is a CD4+ T cell-mediated animal model of the Guillain-Barré syndrome in human. The role of NK cells in the initiation and development of EAN remains unclear. In the present study, we demonstrate that anti-NKR-P1A monoclonal antibody (mAb) treatment in vivo did not affect the initiation and development of clinical EAN in Lewis rats induced by immunization with peripheral nerve myelin P0 protein peptide 180-199 and Freund's complete adjuvant, as well as the proportion of NKR-P1A+ cells (including NK cells and NKT cells) in the spleen. Furthermore, inflammatory cell infiltrations and demyelination in the peripheral nervous system (PNS) and in vitro P0 peptide 180-199-specific splenocyte proliferation were not different in anti-NKR-P1A mAb-treated rats compared to the control antibody-treated rats. The cytotoxic activity of NKR-P1A+ cells, determined by NK cell-sensitive K562 cells as target cells, decreased markedly in anti-NKR-P1A mAb-treated rats, suggesting that decrease of the cytotoxic activities of NKR-P1A+ cells is not sufficient to alter clinical EAN, although NKR-P1A+ cells may participate in the pathogenesis of T cell-mediated autoimmune diseases, such as EAN, by the mechanisms that involve the release of cytokines.
authors.affiliation: Division of Geriatric Medicine, Department of Neurotec, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden.
authors.forename: Shuo
authors.initials: S
authors.lastname: Yu
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhu
authors.forename: Zhiguo
authors.initials: Z
authors.lastname: Chen
authors.forename: Mats
authors.initials: M
authors.lastname: Alheim
authors.forename: Anna
authors.initials: A
authors.lastname: Ljungberg
authors.forename: Jie
authors.initials: J
authors.lastname: Zhu
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000954:Antigens, Surface / Q000276:immunology*; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D003711:Demyelinating Diseases / Q000276:immunology; D005434:Flow Cytometry; D020275:Guillain-Barre Syndrome / Q000276:immunology / Q000503:physiopathology; D007694:Killer Cells, Natural / Q000276:immunology*; D037181:Lectins, C-Type; D008297:Male; D018993:Myelin P0 Protein / Q000494:pharmacology; D055651:NK Cell Lectin-Like Receptor Subfamily B; D009444:Neuritis, Autoimmune, Experimental / Q000276:immunology* / Q000503:physiopathology*; D010446:Peptide Fragments / Q000494:pharmacology; D010525:Peripheral Nerves / Q000276:immunology / Q000503:physiopathology; D051381:Rats; D011917:Rats, Inbred Lew; D013154:Spleen / Q000166:cytology / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; C527203:KLRB1 protein, human; D037181:Lectins, C-Type; D018993:Myelin P0 Protein; D055651:NK Cell Lectin-Like Receptor Subfamily B; D010446:Peptide Fragments